02007nas a2200205   4500008004100000022001400041245011900055210006900174260011000243300001400353490000600367520117900373100001801552700002101570700002001591700002301611700001801634700001901652856013001671       2014                        eng d  a2050-750X00aGraphene quantum dots conjugated albumin nanoparticles for targeted drug delivery and imaging of pancreatic cancer0 aGraphene quantum dots conjugated albumin nanoparticles for targe  aTHOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLANDbROYAL SOC CHEMISTRYcJUN  a3190-31950 v23 a<p>Pancreatic cancer is considered to be the deadliest of all cancers due to its poor prognosis and resistance to conventional therapies. In this study, the potential of hyaluronic acid functionalized and green fluorescent graphene quantum dot (GQD)-labeled human serum albumin nanoparticles for pancreatic cancer specific drug delivery and bioimaging was explored. GQDs with tunable fluorescence properties and biocompatibility have attracted much more interest in recent years as compared to their metal semiconductor counterparts. We adopted lawsone (2-hydroxy-1,4-naphthoquinone) as a novel reducing agent for the synthesis of quantum dots and, in addition to excellent fluorescence of the synthesized GQDs, a good quantum yield of similar to 14% was also obtained. Gemcitabine, the most preferred drug for pancreatic cancer treatment, was encapsulated in albumin nanoparticles, and it was observed that our nanoformulation significantly enhanced the bioavailability and sustained release property of the drug to pancreatic cancer cells in vitro. Moreover, the GQD-mediated bioimaging was excellent and enhanced the efficacy of our system as a drug delivery vehicle.</p>1 aNigam, Preeti1 aWaghmode, Shobha1 aLouis, Michelle1 aWangnoo, Shishanka1 aChavan, Pooja1 aSarkar, Dhiman  uhttp://library.ncl.res.in/content/graphene-quantum-dots-conjugated-albumin-nanoparticles-targeted-drug-delivery-and-imaging-000521nas a2200133   4500008004100000245007500041210006900116260002000185100002500205700001700230700002200247700001900269856009900288       2016                        eng d00aGraphene quantum dots - from emergence to nanotheranostic applications0 aGraphene quantum dots from emergence to nanotheranostic applicat  aCroatiabIntech1 aJoshi, Preeti, Nigam1 aKundu, Subir1 aSanghi, Sunil, K.1 aSarkar, Dhiman  uhttp://library.ncl.res.in/content/graphene-quantum-dots-emergence-nanotheranostic-applications03044nas a2200229   4500008004100000245017800041210006900219260000800288300001400296490000700310520219500317100001502512700001602527700001902543700002302562700002102585700001902606700002102625700002502646700001702671856012602688       2016                        eng d00aGSH Induced controlled release of levofloxacin from a purpose-built prodrug: luminescence response for probing the drug release in escherichia coli and staphylococcus aureus0 aGSH Induced controlled release of levofloxacin from a purposebui  cSEP  a2062-20700 v273 a<p>Fluoroquinolones are third-generation broad spectrum bactericidal antibiotics and work against both Gram-positive and Gram-negative bacteria. Levofloxacin (L), a fluoroquinolone, is widely used in anti-infective chemotherapy and treatment of urinary tract infection and pneumonia. The main pathogen for urinary tract infections is Escherichia colt, and Streptococcus pneumoniae is responsible for pneumonia, predominantly a lower respiratory tract infection. Poor permeability of L leads to the use of higher dose of this drug and excess drug in the outer cellular fluid leads to central nervous system (CNS) abnormality. One way to counter this is to improve the lipophilicity of the drug molecule, and accordingly, we have synthesized two new Levofloxacin derivatives, which participated in the spatiotemporal release of drug via disulfide bond cleavage induced by glutathione (GSH). Recent studies with Streptococcus mutants suggest that it is localized in epithelial lining fluid (ELF) of the normal lower respiratory tract and the effective [GSH] in ELF is similar to 430 mu M. E. coli typically cause urinary tract infections and the concentration of GSH in porcine bladder epithelium is reported as 0.6 mM for a healthy human. Thus, for the present study we have chosen two important bacteria (Gram + ve and Gram - ve), which are operational in regions having high extracellular GSH concentration. Interestingly, this supports our design of new lipophilic Levofloxacin based prodrugs, which released effective drug on reaction with GSH. Higher lipophilicity favored improved uptake of the prodrugs. Site specific release of the drug (L) could be achieved following a glutathione mediated biochemical transformation process through cleavage of a disulfide bond of these purpose-built prodrugs. Further, appropriate design helped us to demonstrate that it is possible also to control the kinetics of the drug release from respective prodrugs. Associated luminescence enhancement helps in probing the release of the drug from the prodrug in bacteria and helps in elucidating the mechanistic pathway of the transformation. Such an example is scarce in the contemporary literature.</p>1 aPal, Suman1 aRamu, Vadde1 aTaye, Nandaraj1 aMogare, Devraj, G.1 aYeware, Amar, M.1 aSarkar, Dhiman1 aReddy, Srinivasa1 aChattopadhyay, Samit1 aDas, Amitava  uhttp://library.ncl.res.in/content/gsh-induced-controlled-release-levofloxacin-purpose-built-prodrug-luminescence-response